Can-Fite BioPharma (CANF) Registration Filing summary

Company overview and business model

• Advanced clinical-stage biopharmaceutical company developing orally bioavailable small molecule therapeutics for cancer, liver, and inflammatory diseases, targeting the A3 adenosine receptor (A3AR).

• Drug pipeline consists of synthetic, highly specific agonists and allosteric modulators targeting A3AR, which is overexpressed in pathological cells but low in normal cells.

• Incorporated in Israel in 1994, with principal executive offices in Ramat Gan, Israel.

Financial performance and metrics

• As of June 30, 2024, pro forma total capitalization was $8.4 million, with shareholders' equity of $6.95 million after warrant repricing and related transactions.

• 1,828,928,493 ordinary shares outstanding as of August 29, 2024; up to 3,603,214,293 shares could be outstanding assuming full warrant exercise.

Use of proceeds and capital allocation

• No proceeds from the resale of shares by selling shareholders; proceeds from warrant exercises (if not cashless) could total approximately $13.3 million.

• Any proceeds from warrant exercises will be used for research and development, general and administrative expenses, and working capital.

• Pending use, proceeds will be invested in short-term, interest-bearing securities or U.S. government obligations.